STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4.
Wang H, Huo X, Yang XR, He J, Cheng L, Cheng L, Wang N, Deng X, Jin H, Wang N, Wang C, Zhao F, Fang J, Yao M, Fan J, Qin W. · 2017
Read STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. by Wang H, Huo X, Yang XR, He J, Cheng L, Cheng L, Wang N, Deng X, Jin H, Wang N, Wang C, Zhao F, Fang J, Yao M, Fan J, Qin W. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5558651.txt.
Introduction
Wang and co-authors present a research article in Molecular Cancer. Their subject is a long noncoding RNA called HOXD-AS1 in liver cancer. Such RNAs do not code for proteins, yet they can steer cell behavior. The team found this one raised in tumor tissue.
High levels linked to poor survival and more advanced disease. A protein named STAT3 switches the RNA on. Lowering HOXD-AS1 slowed cancer cell migration and invasion in lab tests. It also cut lung spread in mice. The RNA acts as a sponge for a small RNA, miR-130a-3p. That frees a gene called SOX4 to drive spread. Readers learn how a noncoding RNA can push cancer to new sites.
Catalog record
| CREATOR | Wang H, Huo X, Yang XR, He J, Cheng L, Cheng L, Wang N, Deng X, Jin H, Wang N, Wang C, Zhao F, Fang J, Yao M, Fan J, Qin W. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4 By Hui Wang, Xisong Huo, Xin-Rong Yang, Jia He, Lijun Cheng, Na Wang, Xuan Deng, Haojie Jin, Ning Wang, Cun Wang, Fangyu Zhao, Jingyuan Fang Published in: Molecular Cancer DOI: 10.1186/s12943-017-0680-1 ABSTRACT Background Several of the thousands of human long noncoding RNAs (lncRNAs) have been functionally characterized, yet their potential involvement in hepatocellular carcinoma (HCC) remains poorly understood. Methods LncRNA-HOXD-AS1 was identified by microarray and validated by real-time PCR. The clinicopathological significance of HOXD-AS1 was analyzed by Kaplan-Meier method. Chromatin immunoprecipitation was conducted to examine the mechanism of HOXD-AS1 upregulation. The role of HOXD-AS1 in HCC cells was assessed both in vitro and in vivo. ceRNA function of HOXD-AS1 was evaluated by RNA immunoprecipitation and biotin-coupled miRNA pull down assays. Results In this study, we found that HOXD-AS1 was significantly upregulated in HCC tissues. Clinical investigation demonstrated high expression level of HOXD-AS1 was associated with poor prognosis and high tumor node metastasis stage of HCC patients, and was an independent risk factor for survival. Moreover, our results revealed that STAT3 could specifically interact with the promoter of HOXD-AS1 and activate HOXD-AS1 transcription. Knockdown of HOXD-AS1 significantly inhibited migration and invasion of HCC cells in vitro and distant lung metastasis in vivo. Additionally, HOXD-AS1 was enriched in the cytoplasm, and shared miRNA response elements with SOX4. Overexpression of HOXD-AS1 competitively bound to miR-130a-3p that prevented SOX4 from miRNA-mediated degradation, thus activated the expression of EZH2 and MMP2 and facilitated HCC metastasis. Conclusions In summary, HOXD-AS1 is a prognostic marker for HCC patients and it may play a pro-metastatic role in hepatocarcinogenesis. Electronic supplementary material The online version of this article (doi:10.1186/s12943-017-0680-1) contains supplementary material, which is available to authorized users. BACKGROUND Hepatocellular carcinoma (HCC) is one of the most frequently diagnosed malignancies and the third most common cause of cancer-related death worldwide. Despite the use of innovative therapeutic strategies for HCC, survival rate is still poor for HCC patients. It is mainly due to the high rates of recurrence and metastasis after surgical resection [1, 2]. Although great progress has been achieved in the identification of protein-coding genes or small noncoding RNAs, i.e., microRNAs, in development and progression of HCC [3, 4], little is known about the roles of long noncoding RNAs (lncRNAs) in hepatocarcinogenesis. LncRNAs are a class of noncoding RNA transcripts that have recently attracted great research interest. So far, a large range of functions have been attributed to lncRNAs, such as control of muscle differentiation [5], reprogramming of induced pluripotent stem cells [6], and modulation of cell apoptosis and invasion [7]. Indeed, accumulating evidence indicates that alteration and dysfunction of lncRNAs have been shown to result in aberrant genes expression that promotes tumor formation, progression and metastasis of many cancer types [8–13]. Several recent reports have described that lncRNAs are important cis- or trans-regulators of genes activities through a variety of mechanisms. In the nucleus, lncRNAs can function as scaffolds to bring proteins to form ribonucleoprotein complexes and as guides to recruit chromatin-modifying complexes to target genes [14–16]. In the cytoplasm, lncRNAs also can function as competing endogenous RNAs (ceRNAs) by competitively binding miRNAs, thereby modulating the derepression of miRNAs targets [17, 18]. To date, only few studies have documented lncRNAs in HCC [19–22] and the underlying mechanisms remain largely unknown. SOX4, a member of the SOX (SRY-related HMG-box) gene family that containing the highly conserved HMG-domain responsible for specific DNA binding was identified as a common transcription factor that is involved in many cancer progression [23–25]. However, its direct target genes that mediate cancer progression are not well defined. In the current study, using gene expression profiling analysis we discovered a lncRNA HOXD-AS1 was upregulated in HCC and significantly correlated with poor prognosis of HCC patients. Meanwhile, we demonstrated that HOXD-AS1 promoted HCC metastasis by acting as a ceRNA to upregulate the expression of SOX4 and activated the expression of EZH2 and MMP2, two direct target genes of SOX4. METHODS Cell culture Human HCC cell lines SNU449, Huh28, SMMC-7721, Huh7, Hep3B, and human embryonic kidney cell line HEK-293 T were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% fetal bovine serum, 100U/ml penicillin, and 100 μg/ml streptomycin. All of cell lines were cultured in a humidified chamber with 5% CO2 at 37 °C. The cells were tested regularly for mycoplasma (R&D Systems’ new MycoProbe Mycoplasma Detection Kit). Patients and specimens Primary human HCC cancerous tissues (C) and corresponding adjacent noncancerous liver tissues (N) were acquired from the surgical specimen archives of Zhongshan Hospital, Shanghai, China. HCC was on the basis of CT, ultrasound or MRI characteristics and biochemistry (AFP serology and liver function enzymes), and was confirmed by histopathology, according to the American Association for the Study of Liver Diseases guidelines [26]. The inclusion criteria were that the samples contained matched tumors (percentage of tumor cells >70%) and corresponding normal liver tissue (>5 cm laterally from the edge of the cancerous region), the patient had a single primary lesion, and no neoadjuvant therapy. The patients who had the history of other solid tumors, had the secondary liver cancer from other primary regions, or did not have the follow-up information were excluded from this study. Tumor differentiation was graded using the Edmondson grading system. Clinical staging was performed according to the tumor-node-metastasis (TNM) staging system. The follow-up procedures and postoperative treatments were based on a uniform guideline and have been described previously [27]. Overall survival (OS) was calculated from the date of surgery to the date of death. Data were censored at the last follow-up visit or at the time of a patient’s death without relapse. Ethical approval was obtained from the Zhongshan Hospital Research Ethics Committee, and written informed consent was obtained from each patient. Microarray analysis Total RNAs were isolated from the paired tissue samples of 14 HCC patients and purified using TRIzol reagent (Invitrogen, Carlsbad, CA) and RNeasy mini kit (Qiagen Inc, Valencia, CA) according to the manufacturer's protocol. Clinicopathological characteristics of the 14 HCC patients are provided in Additional file 1: Table S1. Following RNA isolation and cDNA synthesis, biotin-labeled cRNA was prepared by Enzo® BioArrayTM HighYieldTM RNA transcript label kit (Enzo life sciences, INC), then hybridized to the Affymetrix Gene Chip Human Genome U133 Plus 2.0 Array (Santa Clara, CA). Differentially expressed lncRNAs were analyzed as described previously [28]. 5’and 3’ rapid amplification of cDNA ends (RACE) analyses 5’RACE and 3’RACE analyses were performed with 5 μg of total RNA. The SMARTer™ RACE cDNA kit (Clontech) was used according to the manufacturer’s instructions. The gene specific primers used for PCR are presented in Additional file 2: Table S2. Nuclear fractionation Nuclear fractionation was performed with a PARIS™ Kit (Ambion, Austin, TX). For nuclear fractionation, 1 × 107 cells (Huh7 or SMMC-7721) were collected and resuspended in the cell fraction buffer and incubated on ice for 10 min. After centrifugation, supernatant and nuclear pellet were preserved for RNA extraction using a cell disruption buffer according to the manufacturer’s instructions. Fluorescence in situ hybridization analysis Probe for HOXD-AS1 was presented in Additional file 2: Table S2. SMMC-7721 and Huh7 cells were used for RNA-FISH analysis. Cell suspension was